Real-World Comparison of Semaglutide and Tirzepatide for Obesity

2,549 patient records from a nationwide multicenter study comparing the short-term safety and efficacy of semaglutide and tirzepatide for obesity. The data includes adverse event rates, treatment discontinuation, and body weight loss outcomes up to 6 months. This supplementary material was uploaded by figshare admin karger in April 2026.

Use Cases

• Compare short-term adverse event profiles between semaglutide and tirzepatide based on reported gastrointestinal, musculoskeletal, and allergic reactions.
• Analyze treatment persistence and discontinuation rates due to adverse events, with a focus on pancreatic events.
• Model early body weight loss trajectories and metabolic outcomes over a 6-month period for the two treatments.
• Conduct subgroup analyses on treatment efficacy in patients with and without type 2 diabetes mellitus.

Strengths

• Includes 2,549 patient records from a nationwide multicenter study, providing a substantial real-world cohort.
• Reports specific comparative statistics, such as a 12.6% median body weight loss for semaglutide versus 14.4% for tirzepatide at 6 months.
• Contains detailed adverse event data including time to onset and dose at occurrence.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 27.0 KB, indicating limited scope, likely containing summary results rather than raw patient-level data.

Provenance

Source

figshare admin karger

Collection Method

Nationwide multicenter observational study.

Freshness

Last updated 2026-04-24 07:55:43; freshness should be verified.

Geography

Nationwide (country unspecified).